Biomarker-stratified first-line treatment of right-sided metastatic colon cancer with interdisciplinary collaboration in the IVOPAK II trial

Vitali F, Merkel S, Schubart C, Schmid A, Eckstein M, Stöhr R, Kersting S, Hartmann A, Grützmann R, Wein A (2024)

Publication Type: Journal article

Publication year: 2024

Journal

Anti-Cancer Drugs Lippincott, Williams & Wilkins

Abstract

Patients with right-sided metastatic colon carcinoma have a significantly worse prognosis than those with left-sided colorectal cancer (CRC), regardless of treatment. The aim of the prospective IVOPAK II study was to implement an interdisciplinary guideline-conform personalized CRC palliative therapy of metastatic colorectal carcinoma and to improve the overall survival (OS) by multidisciplinary approach via secondary metastatic resection. We present the efficacy data of first-line treatment and the benefit of interdisciplinary collaboration of right-sided metastatic colon carcinoma patients: n = 25. RAS mutation: n = 20 (80%): received systemic first-line treatment: FOLFIRI plus bevacizumab. All-RAS-wildtype: n = 5 (20%): received systemic first-line treatment: FOLFIRI plus cetuximab. Last date evaluation: 31 January 2024. Median age: 59.6 years (range 42-71), men/women: 14/11. Eastern Cooperative Oncology Group (ECOG) index: 0/1/2 : 11/10/4. Evaluable for response: n = 25. Complete response: n = 0, partial response: n = 14 (56%), stable disease: n = 8 (32%), progressive disease: n = 3 (12%), early tumor shrinkage: n = 13 (52%), estimates progression-free survival: 13 months (95% CI 8-17 months), estimated OS: 48 months (95% CI 25-71 months), median follow-up: 26 months (1-61 months), no evidence of disease: n = 4 (16%). A chemotherapy doublette regimen with FOLFIRI plus a biological as first-line treatment shows promising efficacy and secondary metastatic resection after interdisciplinary discussion was associated with a survival benefit in right-sided metastatic colon carcinoma.

Authors with CRIS profile

Francesco Vitali Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology Susanne Merkel Department of Surgery Christoph Schubart Institute of Pathology Axel Schmid Institute of Radiology Markus Eckstein Institute of Pathology Robert Stöhr Lehrstuhl für Allgemeine Pathologie und Pathologische Anatomie Arndt Hartmann Lehrstuhl für Allgemeine Pathologie und Pathologische Anatomie Robert Grützmann Department of Surgery Axel Wein Medizinische Fakultät

How to cite

APA:

Vitali, F., Merkel, S., Schubart, C., Schmid, A., Eckstein, M., Stöhr, R.,... Wein, A. (2024). Biomarker-stratified first-line treatment of right-sided metastatic colon cancer with interdisciplinary collaboration in the IVOPAK II trial. Anti-Cancer Drugs. https://doi.org/10.1097/CAD.0000000000001636

MLA:

Vitali, Francesco, et al. "Biomarker-stratified first-line treatment of right-sided metastatic colon cancer with interdisciplinary collaboration in the IVOPAK II trial." Anti-Cancer Drugs (2024).

BibTeX: Download